Search Within

Lorenzo Falchi

Formats
  1. Meeting Abstract (96)
  2. Journal Article (23)
  3. Research Letter (6)
  4. Review (5)
  5. Correspondence (2)
  6. Editorial (1)
  7. Guidelines (1)
Groups
  1. Department of Medicine (134)
  2. Hematologic Malignancies, Division of (134)
  3. Center for Hematologic Malignancies (88)
  4. Lymphoma (78)
  5. Sloan Kettering Institute Postdocs (57)
  6. Survivorship Research (54)

More Groups

People
  1. Gilles Salles (66)
  2. Andrew Zelenetz (64)
  3. Maria Palomba (63)
  4. Anita Kumar (61)
  5. Ariela Noy (57)
  6. Alison Moskowitz (54)

More People

Years
  1. 2025 (8)
  2. 2024 (40)
  3. 2023 (43)
  4. 2022 (23)
  5. 2021 (14)
  6. 2020 (6)
Publications
  1. Blood (67)
  2. Journal of Clinical Oncology (11)
  3. Hematological Oncology (9)
  4. Blood Advances (5)
  5. Clinical Lymphoma, Myeloma and Leukemia (5)
  6. Leukemia and Lymphoma (5)

More Publications

Publishers
  1. American Society of Hematology (72)
  2. American Society of Clinical Oncology (11)
  3. Wiley Blackwell (9)
  4. Elsevier Inc. (8)
  5. Taylor & Francis Group (5)
  6. Ferrata Storti Foundation (4)

More Publishers

Results (134)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 2 study of minimal residual disease (MRD)-adapted front line venetoclax and obinutuzumab in fit patients with chronic lymphocytic leukemia (CLL): Effect of obinutuzumab on tumor lysis syndrome (TLS) risk and safety of outpatient venetoclax dose escalation
    Meeting Abstract

    Roeker, L. E.; Zelenetz, A. D.; Park, J. H.; Derkach, A.; Geyer, M. B.; Islam, P.; Falchi, L.; Palomba, M. L.; Kumar, A.; Salles, G.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Responses and outcomes after second-line therapy in transplant-eligible patients with DLBCL relapse over 1 year after first-line therapy
    Meeting Abstract

    Qualls, D. A.; Shah, G. L.; Shouval, R.; Caron, P.; David, K. A.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; Intlekofer, A. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Impact of early histological transformation on survival in patients with follicular lymphoma
    Meeting Abstract

    Luttwak, E.; Qiu, A.; Okwali, M.; Rivas-Delgado, A.; Isgor, I.; Boardman, A. P.; Caron, P.; David, K. A.; Falchi, L.; Ghione, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • CNS radiotherapy as bridging prior to CAR T-cell therapy for non-Hodgkin B-cell lymphoma
    Meeting Abstract

    Cederquist, G.; Schefflein, J.; Devlin, S. M.; Hubbeling, H.; Tringale, K.; Shah, G. L.; Tomas, A. A.; Shouval, R.; Hajj, C.; Fregonese, B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Infectious complications in patients with relapsed or refractory (R/R) Non-Hodgkin's lymphoma (NHL) treated with the anti-CD20xCD3 bispecific antibody (BsAb) mosunetuzumab
    Meeting Abstract

    Shahid, Z.; Okwali, M.; Joseph, A.; Seo, S. K.; Lue, J. K.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Ghione, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Real-world outcomes in patients with transformed follicular lymphoma treated with CD19-targeting CAR-T therapy
    Meeting Abstract

    Rivas-Delgado, A.; Luttwak, E.; Drill, E.; Goldstein, I.; Landego, I.; Tomas, A. A.; Parascondola, A.; Saldia, A.; Caron, P.; Dahi, P. B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of limited stage high grade B-cell lymphoma with MYC/BCL2 and/or BCL6 rearrangements: A single center experience
    Meeting Abstract

    Lue, J. K.; Luttwak, E.; Caron, P.; Boardman, A. P.; David, K. A.; Rivas-Delgado, A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Hamlin, P. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Potent CD8+T-cell proliferation and effector differentiation following subcutaneous (SC) mosunetuzumab administration in patients with untreated, high tumor-burden follicular lymphoma (FL)
    Meeting Abstract

    Falchi, L.; Lin, Y. H.; Melendez, L.; Ghione, P.; Owens, C.; Hamlin, P. A.; Lue, J. K.; Epstein-Peterson, Z. D.; Kumar, A.; Palomba, M. L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Brentuximab vedotin-based regimens for older patients with newly diagnosed classical Hodgkin lymphoma -Real world experience
    Meeting Abstract

    Luttwak, E.; Ganesan, N.; Boardman, A. P.; Caron, P.; David, K. A.; Rivas-Delgado, A.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Glofitamab monotherapy in relapsed or refractory large B-cell lymphoma: Extended follow-up from a pivotal phase II study and subgroup analyses in patients with prior chimeric antigen receptor T-cell therapy and by baseline total metabolic tumor volume
    Meeting Abstract

    Hutchings, M.; Carlo-Stella, C.; Morschhauser, F.; Falchi, L.; Bachy, E.; Cartron, G.; Khan, C.; Tani, M.; Martinez-Lopez, J.; Bartlett, N. L.; more...
    Blood (2023)

    Fulltext@MSK | Save